These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18028021)

  • 1. Quality of life and adjuvant systemic therapy for early-stage breast cancer.
    Grimison PS; Stockler MR
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1123-34. PubMed ID: 18028021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early-stage breast cancer - strategies for adjuvant systemic therapy].
    Görner M; Just M; Gerull S
    Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):230-8. PubMed ID: 18716990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs.
    Elkin EB; Weinstein MC; Kuntz KM; Bunnell CA; Weeks JC
    Breast Cancer Res Treat; 2005 Sep; 93(1):25-34. PubMed ID: 16184455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors.
    Knobf MT
    Oncologist; 2006 Feb; 11(2):96-110. PubMed ID: 16476831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy.
    Navari RM; Brenner MC; Wilson MN
    Breast Cancer Res Treat; 2008 Nov; 112(1):197-201. PubMed ID: 18064563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivorship and complications of treatment in breast cancer.
    Mrozek E; Shapiro CL
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):211-22, 238. PubMed ID: 16166992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff.
    Groenvold M; Fayers PM; Petersen MA; Sprangers MA; Aaronson NK; Mouridsen HT
    Breast Cancer Res Treat; 2007 Jun; 103(2):185-95. PubMed ID: 17039266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy.
    Davidson B; Vogel V; Wickerham L
    J Support Oncol; 2007 Mar; 5(3):139-43. PubMed ID: 17410813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early breast cancer therapy and cardiovascular injury.
    Jones LW; Haykowsky MJ; Swartz JJ; Douglas PS; Mackey JR
    J Am Coll Cardiol; 2007 Oct; 50(15):1435-41. PubMed ID: 17919562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary systemic therapy in breast cancer: past lessons and new approaches.
    Herold CI; Marcom PK
    Cancer Invest; 2008 Dec; 26(10):1052-9. PubMed ID: 19093262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.